Steven Cohen Bristol Myers Squibb CO Call Options Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $4 Million - $5.22 Million	100,800 Added 26.97%	474,600 $24.6 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $4.93 Million - $6.49 Million	122,400 Added 48.69%	373,800 $15.5 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $67,172 - $76,160	1,400 Added 0.56%	251,400 $13.6 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $12.1 Million - $14.5 Million	250,000 New	250,000 $12.8 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $6.06 Million - $6.87 Million	-92,200 Reduced 60.42%	60,400 $4.19 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $1.02 Million - $1.21 Million	14,900 Added 10.82%	152,600 $11 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $17,901 - $10.6 Million	137,700 New	137,700 $9.79 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $16.1 Million - $18.8 Million	-300,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $101 Million - $118 Million	-1,700,000 Reduced 85.0%	300,000 $17.8 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $115 Million - $131 Million	2,000,000 New	2,000,000 $124 Million

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $127B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.